Press Center

Lidings invites you to a seminar on the hottest and most striking amendments to labor legislation — as bright as autumn bonfires.

Russian pharmaceutical manufacturers are increasingly looking toward the GCC and MENA regions. But "entering" and "establishing a foothold" are challenges of entirely different magnitudes.

The two key markets in the region — the UAE and Saudi Arabia — despite their undeniable appeal, require fundamentally different approaches.

Together with the Pharvestnik Magazine, Julia Kuzmenko, Counsel and Head of Regulatory Practice at Lidings, examined the nuances of the regulatory architecture in these two jurisdictions.

Lidings announces the launch of a new Regulatory Practice. The practice will be headed by the firm's Counsel Julia Kuzmenko.

The creation of the new practice continues the development of Lidings' industry expertise and responds to the growing demand from businesses for comprehensive support amid increasingly complex government regulation and new mandatory requirements.

We invite you to a webinar on antitrust risks for pharmaceutical companies when setting prices for medicinal products.

As part of the implementation of the Strategy for the Development of the Pharmaceutical Industry through 2030, approved by Decree of the Government of the Russian Federation No. 1495-r of 7 June 2023 (“Pharma Strategy 2030”), and discussions at the “Healthy Society” forum organized by the Roscongress Foundation with the support of the Ministry of Health (16–17 March 2026, Moscow) (“Forum”), key areas of state support for domestic drug developers and manufacturers were identified, including subsidies for clinical trials .

In addition to existing support programs, subsidies for clinical trials at all stages will help overcome the financing barrier for high-risk phases of medicines clinical trials and accelerate the market launch of medicines. The combination of current and planned measures will create the legal and economic foundation for strengthening the production and technological capacity of the domestic pharmaceutical industry and increasing its presence in international markets.

Below, we will examine planned initiatives and support measures for pharmaceutical manufacturers that have already been implemented.

April 9^th,2026 annual conference Pharmaceuticals – 2026: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.

As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss how the market has changed in 2025 and what awaits us in 2026.

On February 17, 2026, the annual flagship seminar of Lidings, "Predictions 2026: Crystal Clarity Instead of Legal Fog," was held at the Hotel Metropol.

The event marked the beginning of a series of celebrations dedicated to the firm's 20th anniversary and brought together over 70 representatives from 50 Russian and international companies.

Lidings' lawyers together with invited speakers from the corporate sector discussed key legislative changes and shared current trends and practical tools.

2026 is a special year for our team — it marks our 20th anniversary. And we are especially pleased to kick it off with a seminar where we will look into the "Crystal of Predictions": back to the past — to review the key legal developments of the past year, and forward to the future — to share crystal-clear insights on the key business trends awaiting in 2026.

In recent years, artificial intelligence (AI) has evolved from an experimental technology into one of the key drivers of transformation in the pharmaceutical industry and the healthcare system as a whole. Machine learning and big data analysis algorithms are used at all stages of the drug life cycle—from molecular target discovery and molecule design to clinical trials, pharmacovigilance, and personalized therapy. At the same time, AI is increasingly being used directly in medical practice: in diagnosis, disease progression prediction, clinical decision support, and robotic surgery.

Such widespread implementation of AI is accompanied by significant legal, ethical, and regulatory challenges. These include the opacity of algorithms ("black box"), the risk of systematic errors and data bias, issues of liability allocation between the physician, the medical organization, and the developer, as well as the protection of patients' personal medical data. This review combines an analysis of AI regulation in pharmaceuticals and medicine in Russia, the European Union, and the United States with practical cases of AI use and court practice, forming a comprehensive picture of the current state and trends in development.